Associated Papers
Comparative analysis of web-based programs for single amino acid substitutions in proteins.
Choudhury A et al.
Plos One, 2022
Complete Screening of Exons 2, 3, and 4 of KRAS and NRAS Genes Reveals a Higher Number of Clinically Relevant Mutations than Food and Drug Administration Quantitative Polymerase Chain Reaction-Based Commercial Kits.
Sánchez-Ibarra HE et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion, 2020
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Bisht S et al.
Medical Oncology (northwood, London, England), 2014
Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.
Yilmaz A et al.
International Journal of Environmental Research and Public Health, 2014
Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2014
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.
Yanus GA et al.
Medical Oncology (northwood, London, England), 2013
Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR.
Miyano S et al.
Experimental and Therapeutic Medicine, 2012
[Comparison of different methods of molecular-genetic analysis of somatic mutations in K-ras gene in patients with colorectal cancer].
Amosenko FA et al.
Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2012
Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK.
Cust AE et al.
Journal of Medical Genetics, 2011
Functional analysis of CDKN2A/p16INK4a 5'-UTR variants predisposing to melanoma.
Bisio A et al.
Human Molecular Genetics, 2010
The status of KRAS mutations in patients with non-small cell lung cancers from mainland China.
Li M et al.
Oncology Reports, 2009
CDKN2A mutations in melanoma families from Uruguay.
Larre Borges A et al.
The British Journal of Dermatology, 2009
Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2009